189 related articles for article (PubMed ID: 19238439)
1. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Mateo M; Maynard L; Vischer C; Bianciardi P; Miró G
Parasitol Res; 2009 Jul; 105(1):155-62. PubMed ID: 19238439
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
4. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Miró G; Oliva G; Cruz I; Cañavate C; Mortarino M; Vischer C; Bianciardi P
Vet Dermatol; 2009 Oct; 20(5-6):397-404. PubMed ID: 20178476
[TBL] [Abstract][Full Text] [Related]
5. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.
Slappendel RJ; Teske E
Vet Q; 1997 Mar; 19(1):10-3. PubMed ID: 9225422
[TBL] [Abstract][Full Text] [Related]
6. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
7. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
8. Owners' experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study.
de Jong MK; van Eijk D; Broere F; Piek CJ
Vet Rec; 2024 Jun; 194(11):e4089. PubMed ID: 38809570
[TBL] [Abstract][Full Text] [Related]
9. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
[No Abstract] [Full Text] [Related]
10. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
Pennisi MG; Lo Giudice S; Masucci M; De Majo M; Reale S; Vitale F
Vet Res Commun; 2008 Sep; 32 Suppl 1():S303-5. PubMed ID: 18683068
[No Abstract] [Full Text] [Related]
11. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
Woerly V; Maynard L; Sanquer A; Eun HM
Parasitol Res; 2009 Aug; 105(2):463-9. PubMed ID: 19322588
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
Costa Filho AV; Lucas IC; Sampaio RN
Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.
Corpas-López V; Merino-Espinosa G; Acedo-Sánchez C; Díaz-Sáez V; Navarro-Moll MC; Morillas-Márquez F; Martín-Sánchez J
Vet Res Commun; 2018 Jun; 42(2):121-130. PubMed ID: 29453596
[TBL] [Abstract][Full Text] [Related]
16. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
[TBL] [Abstract][Full Text] [Related]
17. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
Torres M; Bardagí M; Roura X; Zanna G; Ravera I; Ferrer L
Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
[TBL] [Abstract][Full Text] [Related]
18. Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate.
Saridomichelakis MN; Xenoulis PG; Chatzis MK; Kasabalis D; Steiner JM; Suchodolski JS; Petanides T
Vet Parasitol; 2013 Oct; 197(1-2):22-8. PubMed ID: 23685064
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
[TBL] [Abstract][Full Text] [Related]
20. Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.
Miró G; Gálvez R; Fraile C; Descalzo MA; Molina R
Parasit Vectors; 2011 Apr; 4():52. PubMed ID: 21489241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
